Mylan works with government, trade associations, healthcare providers, patient-advocacy groups and others to shape policies that help people across the nation enjoy better health.
Mylan has a decades-long track record of expanding people’s access to medicine, particularly by making more-affordable generic versions of brand name drugs – expertise we’re now bringing to biologics, insulins and other complex medicines.
Helped establish the generic industry’s first trade association
Helped give rise to legislation creating the modern generics industry
Helped modernize Medicare, including the introduction of a prescription-drug benefit
Led the way to ensure one quality standard for all medicines sold in the U.S.
In 1984, Generic drugs made up only 19% of prescriptions dispensed in the U.S.
In 2017, they made up 90% of prescriptions dispensed
Biologics now account for about 40% of all U.S. drug spending and 70% of spending growth from 2010 to 20151. It’s estimated that the introduction of biosimilars in the U.S. could save the nation’s healthcare system up to $150B in savings2. We believe that if restrictive policies and other barriers to entry are addressed, the savings could be even greater.
Policymakers can help unlock the value of biosimilars in the U.S.
Improve access to biosimilars by STOPPING DELAY
biosimilars such as REMS3 abuse through denied access to samples.
Accelerate GREATER EDUCATION of HCPs5, patients
and others on safety and reliability of biosimilars.
of all people worldwide being treated for HIV/ AIDS depend on a Mylan antiretroviral product.
of Mylan’s active pharmaceutical ingredient manufacturing capacity is devoted to antiretrovirals.